Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ.

PLoS One. 2016 Mar 21;11(3):e0152243. doi: 10.1371/journal.pone.0152243. eCollection 2016. No abstract available.

2.

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ.

PLoS One. 2015 Jul 21;10(7):e0131232. doi: 10.1371/journal.pone.0131232. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0152243. Liu, Xiuqing [corrected to Li, Xiuqing].

3.

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.

Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati N.

Br J Cancer. 2015 Jul 14;113(2):242-51. doi: 10.1038/bjc.2015.228. Epub 2015 Jun 23.

4.

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME.

PLoS One. 2015 Feb 18;10(2):e0117758. doi: 10.1371/journal.pone.0117758. eCollection 2015.

5.

Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Adisetiyo H, Liang M, Liao CP, Jeong JH, Cohen MB, Roy-Burman P, Frenkel B.

J Cell Physiol. 2014 Sep;229(9):1170-6. doi: 10.1002/jcp.24546.

6.

CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features.

Geary LA, Nash KA, Adisetiyo H, Liang M, Liao CP, Jeong JH, Zandi E, Roy-Burman P.

Mol Cancer Res. 2014 Apr;12(4):607-21. doi: 10.1158/1541-7786.MCR-13-0469. Epub 2014 Jan 24.

7.

Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Pham LK, Liang M, Adisetiyo HA, Liao CP, Cohen MB, Tahara SM, Frenkel B, Kasahara N, Roy-Burman P.

Endocr Relat Cancer. 2013 Nov 4;20(6):861-74. doi: 10.1530/ERC-13-0100. Print 2013 Dec.

8.

Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.

Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P.

PLoS One. 2013 Jul 31;8(7):e69484. doi: 10.1371/journal.pone.0069484. Print 2013.

9.

Current mouse and cell models in prostate cancer research.

Wu X, Gong S, Roy-Burman P, Lee P, Culig Z.

Endocr Relat Cancer. 2013 Jun 24;20(4):R155-70. doi: 10.1530/ERC-12-0285. Print 2013 Aug. Review.

10.

VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman IM, Nelson PS, Vessella RL, Davis RJ, Plymate SR, Mercurio AM.

Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9.

11.

α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.

Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, Fitzgerald T, Butterfield J, Charbonneau B, Violette SM, Weinreb PH, Ratliff TL, Liao CP, Roy-Burman P, Vietri M, Lian JB, Stein GS, Altieri DC, Languino LR.

Am J Transl Res. 2012;4(2):165-74. Epub 2012 Apr 10.

12.

A joint effect of new Western diet and retinoid X receptor α prostate-specific knockout with development of high-grade prostatic intraepithelial neoplasia in mice--a preliminary study.

Mao GE, Harris DM, Moro A, Heber D, Roy-Burman P, Zhang ZF, Rao J.

Prostate. 2012 Jul 1;72(10):1052-9. doi: 10.1002/pros.22496. Epub 2012 Feb 7.

13.

An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice.

Ting MC, Liao CP, Yan C, Jia L, Groshen S, Frenkel B, Roy-Burman P, Coetzee GA, Maxson R.

Dis Model Mech. 2012 May;5(3):366-74. doi: 10.1242/dmm.008458. Epub 2012 Jan 25.

14.

PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.

Lim M, Chuong CM, Roy-Burman P.

Horm Cancer. 2011 Oct;2(5):298-309. doi: 10.1007/s12672-011-0084-4.

PMID:
21948155
15.

Cancer stem cells and microenvironment in prostate cancer progression.

Liao CP, Adisetiyo H, Liang M, Roy-Burman P.

Horm Cancer. 2010 Dec;1(6):297-305. doi: 10.1007/s12672-010-0051-5.

PMID:
21761361
16.

TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.

Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA, Jung JU.

PLoS One. 2011 Jan 18;6(1):e16205. doi: 10.1371/journal.pone.0016205.

17.

Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells.

Liao CP, Adisetiyo H, Liang M, Roy-Burman P.

Cancer Res. 2010 Sep 15;70(18):7294-303. doi: 10.1158/0008-5472.CAN-09-3982. Epub 2010 Aug 31.

18.

Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.

Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, Nikitin AY, Roy-Burman P.

Horm Cancer. 2010 Feb;1(1):44-54. doi: 10.1007/s12672-009-0005-y.

19.

Runx2 regulates survivin expression in prostate cancer cells.

Lim M, Zhong C, Yang S, Bell AM, Cohen MB, Roy-Burman P.

Lab Invest. 2010 Feb;90(2):222-33. doi: 10.1038/labinvest.2009.128. Epub 2009 Nov 30.

20.

Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW.

Cell Death Differ. 2010 Mar;17(3):469-81. doi: 10.1038/cdd.2009.148. Epub 2009 Oct 16.

21.

Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma.

Fujino Y, Liao CP, Zhao YS, Pan J, Mathes LE, Hayes KA, Ohno K, Tsujimoto H, Roy-Burman P.

Virology. 2009 Mar 30;386(1):16-22. doi: 10.1016/j.virol.2009.01.021. Epub 2009 Feb 8.

22.

Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.

Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, Lee AS.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9. doi: 10.1073/pnas.0807691105. Epub 2008 Nov 25.

23.

PTEN knockout prostate cancer as a model for experimental immunotherapy.

Haga K, Tomioka A, Liao CP, Kimura T, Matsumoto H, Ohno I, Hermann K, Logg CR, Jiao J, Tanaka M, Hirao Y, Wu H, Kruse CA, Roy-Burman P, Kasahara N.

J Urol. 2009 Jan;181(1):354-62. doi: 10.1016/j.juro.2008.08.124. Epub 2008 Nov 17.

24.

Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ.

Prostate. 2009 Feb 15;69(3):249-62. doi: 10.1002/pros.20877.

25.

A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer.

Yang S, Pham LK, Liao CP, Frenkel B, Reddi AH, Roy-Burman P.

Cancer Res. 2008 Jan 1;68(1):198-205. doi: 10.1158/0008-5472.CAN-07-5074.

26.

Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.

Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, Zhou Z, Nikitin AY, Roy-Burman P.

Cancer Res. 2007 Aug 1;67(15):7525-33.

27.

Prostate stem cells and cancer.

Nikitin AY, Matoso A, Roy-Burman P.

Histol Histopathol. 2007 Sep;22(9):1043-9. doi: 10.14670/HH-22.1043. Review.

PMID:
17523082
28.

Inactivation of Apc in the mouse prostate causes prostate carcinoma.

Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, Zylstra CR, Robinson DR, Roy-Burman P, Shaw AK, Buckner-Berghuis BD, Sigler RE, Resau JH, Sullivan R, Bushman W, Williams BO.

Cancer Res. 2007 Mar 15;67(6):2490-6.

29.

Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.

De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, Coussens LM, Cohen MB.

Cancer Biol Ther. 2006 Dec;5(12):1588-99. Epub 2006 Dec 6. No abstract available.

PMID:
17224636
30.

Not too contemplative but still amazing turns.

Roy-Burman P.

Cancer Biol Ther. 2006 Oct;5(10):1416-9. Epub 2006 Oct 2. No abstract available.

PMID:
17106241
31.

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY.

Cancer Res. 2006 Aug 15;66(16):7889-98.

32.

Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways.

Yang S, Lim M, Pham LK, Kendall SE, Reddi AH, Altieri DC, Roy-Burman P.

Cancer Res. 2006 Apr 15;66(8):4285-90.

33.

Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.

Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P.

Cancer Res. 2006 Feb 15;66(4):2188-94.

34.

Increased expression of osteopontin contributes to the progression of prostate cancer.

Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P.

Cancer Res. 2006 Jan 15;66(2):883-8.

35.

In vivo expression of GFP transgene delivered via a replicating feline leukemia virus.

Pan J, Al-Dubaib M, Liao CP, Fujino Y, Hinton DR, Hayes KA, Mathes LE, Roy-Burman P.

Vet Microbiol. 2005 Oct 31;110(3-4):181-95.

PMID:
16143471
36.

Androgens and prostate cancer: are the descriptors valid?

Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ.

Cancer Biol Ther. 2005 Jan;4(1):4-5.

PMID:
16052746
37.

Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.

Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P.

Cancer Res. 2005 Jul 1;65(13):5769-77.

38.

EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.

39.

Genetically defined mouse models that mimic natural aspects of human prostate cancer development.

Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB.

Endocr Relat Cancer. 2004 Jun;11(2):225-54. Review.

PMID:
15163300
40.

Pten dose dictates cancer progression in the prostate.

Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP.

PLoS Biol. 2003 Dec;1(3):E59. Epub 2003 Oct 27.

41.

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H.

Cancer Cell. 2003 Sep;4(3):209-21.

42.

Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer.

Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P.

Cancer Biol Ther. 2003 Mar-Apr;2(2):179-84.

PMID:
12750559
43.

A potential therapeutic strategy to combat leukemia virus infection.

Pan J, Zhong C, Chang Z, Roy-Burman P.

Cancer Biol Ther. 2003 Jan-Feb;2(1):92-9.

PMID:
12673127
44.

Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer.

Powell WC, Cardiff RD, Cohen MB, Miller GJ, Roy-Burman P.

Curr Drug Targets. 2003 Apr;4(3):263-79. Review.

PMID:
12643476
45.

Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia.

Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ, Roy-Burman P.

Cancer Res. 2002 Sep 1;62(17):5096-105.

46.

Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium.

Huang J, Powell WC, Khodavirdi AC, Wu J, Makita T, Cardiff RD, Cohen MB, Sucov HM, Roy-Burman P.

Cancer Res. 2002 Aug 15;62(16):4812-9.

48.

Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.

Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P.

Mech Dev. 2001 Mar;101(1-2):61-9.

49.

The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells.

Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P.

Cancer Res. 2000 Dec 1;60(23):6730-6.

50.

Inhibition of feline leukemia virus subgroup A infection by coinoculation with subgroup B.

Phipps AJ, Hayes KA, Al-dubaib M, Roy-Burman P, Mathes LE.

Virology. 2000 Nov 10;277(1):40-7.

Supplemental Content

Loading ...
Support Center